Skip to main content

Day: July 15, 2020

Access-Power & Co., Inc. is pleased to announce our next generation of curbside home delivery service called CLONES BY CARS is ONLINE NOW!

GRAND HAVEN, Mich., July 15, 2020 (GLOBE NEWSWIRE) — Access-Power & Co, Inc., (“ACCR or the Company”), a Grand Haven based diversified holding Company is pleased to announce that we have begun taking payments online and over the telephone for our revolutionary new curbside home delivery service of Medical Marijuana Clones and Medical Hemp Clones.  Our business model is a non-THC delivery of baby little live plants.  This is a new trademarked and patent pending service with the US Patent and Trademark Service or http://www.uspto.gov.Our mark publication is found here: https://teas.uspto.gov/submit250/xslt.service?nozip=yes&stamp=USPTO/BAS-2600:1700:d590:6e60:90e9:1330:c123:2efd-20200715113827035902-New/Application-740bc54d78d89b5547b8e1b124b161124d226bd7677d83ed3012b25e7e83bb41&obj=mark.jpgOur new website to generate...

Continue reading

XBiotech annonce avoir découvert que le blocage de l’interleukine-1a réduit les lésions cérébrales et le déficit neurologique à la suite d’un accident vasculaire cérébral

AUSTIN, Texas, 15 juill. 2020 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ : XBIT) a annoncé aujourd’hui la publication de ses résultats dans la prestigieuse revue Circulation éditée par l’American Heart Association. L’article intitulé « Post-Ischemic Administration of IL-1a Neutralizing Antibody Reduces Brain Damage and Neurological Deficit in Experimental Stroke » (L’administration post-ischiémique d’anticorps neutralisant l’IL-1a réduit les dommages cérébraux et le déficit neurologique lors d’accidents vasculaires expérimentaux) indique une utilisation possible de l’anticorps médicamenteux candidat de XBiotech qui bloque l’interleukine-1 alpha (IL-1⍺) dans le cadre d’une thérapeutique visant à réduire les dommages cérébraux et le déficit neurologique après un accident vasculaire....

Continue reading

XBiotech gibt Forschungsergebnis bekannt: die Blockade von Interleukin-1a verringert Hirnschädigungen und neurologische Defizite nach Schlaganfall

AUSTIN, Texas, July 15, 2020 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ: XBIT) hat heute Forschungsergebnisse bekanntgegeben, die in der renommierten Zeitschrift Circulation der American Heart Association veröffentlicht wurden. Die Publikation mit dem Titel Post-Ischemic Administration of IL-1a Neutralizing Antibody Reduces Brain Damage and Neurological Deficit in Experimental Stroke (Postischämische Verabreichung von IL-1a-neutralisierenden Antikörpern reduziert Hirnschäden und neurologische Defizite bei experimentellem Schlaganfall) weist daraufhin, dass der Medikamentenkandidaten-Antikörper von XBiotech, der Interleukin-1-Alpha (IL-1⍺) blockiert, als Therapeutikum zur Verringerung von Hirnschäden und neurologischen Defiziten nach einem Schlaganfall in Frage kommt. Die Forschungsarbeiten wurden von Dr. Giovanni Camici geleitet,...

Continue reading

Union Bankshares Announces Earnings for the three and six months ended June 30, 2020 and Declares Quarterly Dividend

MORRISVILLE, Vt., July 15, 2020 (GLOBE NEWSWIRE) — Union Bankshares, Inc. (NASDAQ – UNB) today announced results for the three and six months ended June 30, 2020 and declared a regular quarterly cash dividend.  Consolidated net income for the three months ended June 30, 2020 were $2.7 million, or $0.60 per share, compared to $2.5 million, or $0.56 per share, for the same period in 2019 and $4.9 million, or $1.09 per share, for the six months ended June 30, 2020, compared to $5.2 million, or $1.15 per share, for the same period in 2019.Second Quarter HighlightsConsolidated net income increased $138 thousand, or 5.4%, to $2.7 million for the second quarter of 2020 compared to the second quarter of 2019 due to increases in net interest income of $271 thousand and noninterest income of $517 thousand, partially offset by increases...

Continue reading

VERB Announces Selected Preliminary Unaudited Operating Results for Second Quarter 2020

NEWPORT BEACH, Calif. and SALT LAKE CITY, July 15, 2020 (GLOBE NEWSWIRE) — VERB Technology Company, Inc. (NASDAQ: VERB) (“VERB” or the “Company”), a leader in interactive video-based sales enablement applications, including interactive livestream ecommerce, webinar, CRM, and marketing applications for entrepreneurs and enterprises, today announced selected preliminary unaudited operating results for the three months ended June 30, 2020.For the three months ended June 30, 2020, the Company reports preliminary Software as a Service (SaaS) recurring subscription revenue of approximately $1,264,000, up from $1,057,000 reported in first quarter 2020; total digital revenue of approximately $1,668,000, up from $1,457,000 reported in first quarter 2020; total non-digital revenue of approximately $941,000, up from...

Continue reading

Inventiva announces the closing of $107.7 million initial public offering on the Nasdaq Global Market

Daix (France), July 15, 2020 – INVENTIVA S.A. (Euronext Paris: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (“NASH”), mucopolysaccharidoses (“MPS”) and other diseases with significant unmet medical need, announced today the closing of its previously announced initial public offering on the Nasdaq Global Market of an aggregate of 7,478,261 new ordinary shares in the form of American Depositary Shares (“ADSs”), each representing one ordinary share, at an offering price of $14.40 per ADS (the “Offering”). Aggregate gross proceeds of the Offering, before deducting underwriting commissions and estimated expenses payable by the Company, were approximately $107.7 million (€94.9 million1). All of the...

Continue reading

Inventiva annonce la réalisation de son introduction en bourse sur le Nasdaq Global Market pour un montant de 107,7 millions de dollars U.S.

Daix (France), le 15 Juillet 2020 – INVENTIVA S.A. (Euronext Paris: IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite non alcoolique (« NASH »), des mucopolysaccharidoses (« MPS ») et d’autres maladies avec un besoin médical non satisfait significatif, annonce aujourd’hui la réalisation de son introduction en bourse sur le Nasdaq Global Market précédemment annoncée pour un nombre total de 7.478.261 actions ordinaires nouvelles, sous la forme d’American Depositary Shares (« ADSs »), chacune d’entre elles représentant une action ordinaire, à un prix de $14,40 par ADS (l’ « Offre »). Le montant brut total de l’Offre, avant déduction des commissions des intermédiaires financiers et frais...

Continue reading

Les Hôtels Baverez : Information Trimestrielle 2e trimestre 2020

LES HOTELS BAVEREZ S.A.2, place des Pyramides 75001 PARISCapital € 10.127.050 – Code NAF 5510 ZR.C.S. PARIS 572 158 558ISIN : FR 0007080254Mnémonique : ALLHBEURONEXT GrowthCommuniqué, Paris le 16 juillet 2020COMMUNIQUE : INFORMATION TRIMESTRIELLE – 2ième TRIMESTRE 2020Variation du Chiffre d’affaires au 30 juin 2020 : – 68,13 %L’activité de l’hôtel Regina a été ralentie par les grèves sur la réforme des retraites de fin d’année 2019 et début 2020. Depuis le 17 mars l’hôtel est totalement fermé à la vente ainsi que les espaces de restauration. Il devrait rouvrir ses portes à la clientèle en septembre.La baisse d’activité de l’hôtel Majestic résulte sur le premier trimestre de l’impact du mouvement précité comme pour l’hôtel Regina, mais également de la fermeture de sept chambres pour création de cinq nouvelles unités. En effet, l’hôtel...

Continue reading

HealthEquity Announces Closing of Sale of Additional Shares

DRAPER, Utah, July 15, 2020 (GLOBE NEWSWIRE) — HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”) today announced the closing of the underwritten public offering of an additional 690,000 shares of its common stock pursuant to the exercise in full by the underwriters of their over-allotment option. The gross proceeds to HealthEquity from the sale of these shares are $37,480,800. HealthEquity intends to use the net proceeds from the offering (including the $257.6 million in gross proceeds from the sale of shares earlier this week) to free up additional capital for organic and inorganic growth by pre-paying $200 million under its term loan facility, with the remaining proceeds to be used for general corporate purposes, which may include additional pre-payments under its term loan facility and/or potential acquisitions.Wells...

Continue reading

Flushing Bank Receives Approval for Second Round of Grant Money from Federal Home Loan Bank of New York’s (FHLBNY) Small Business Recovery Grant Program to Assist Local Small Businesses and Non-Profit Organizations

UNIONDALE, N.Y., July 15, 2020 (GLOBE NEWSWIRE) — Flushing Financial Corporation (the “Company”) (Nasdaq: FFIC), the parent holding company for Flushing Bank (the “Bank”), announced today that the Bank has been approved for a second round of funding from the FHLBNY Small Business Recovery Grant Program. These funds are intended to support the financial security and health of workers employed by organizations that have suffered a decrease in revenue as a result of the ongoing COVID-19 crisis. The Bank will disburse the grant money to local small businesses and non-profit organizations in their market area.John R. Buran, President and CEO, stated, “As a community bank, we recognize our responsibility to help small businesses and non-profit organizations who employ and support the individuals and families struggling in our communities....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.